COMPANY PROFILE

Ocugen

A biotech company specializing in vaccines and gene therapies, focusing on public health and unmet medical needs, with a breakthrough modifier gene therapy platform for multiple retinal diseases and…

East Whiteland Township, United StatesFounded 2013Biotech & Life Sciences

Valuation $423M Market cap · 2026

Revenue $4.4M Latest reported FY

About Ocugen

Ocugen is a fully integrated, patient-centric biotech company dedicated to developing and commercializing novel gene and cell therapies and vaccines. The company focuses on addressing unmet medical needs through innovative solutions. Ocugen's core offerings include a breakthrough modifier gene therapy platform aimed at treating multiple retinal diseases with a single product, advanced vaccine research to combat COVID-19, and cell therapy targeting orthopedic diseases lacking effective treatments. The company operates in the biotechnology sector, serving patients worldwide by leveraging extensive experience from both public and private sectors. Ocugen generates revenue through the development, commercialization, and licensing of its proprietary therapies and vaccines.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2013
Headquarters: East Whiteland Township, United States
Listing: IPO 2014
Employees: 129
Open positions: 9
Dealroom signal: 88.5/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Ophthalmology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO CONVERTIBLE✓Other financing	May 2026	$130M	—	Undisclosed	↗
POST IPO EQUITY✓Other financing	Jan 2026	$0	—	Undisclosed	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$4.7M	+7.4%	−$60M	-1271.5%	−$89M	-1867.7%	$40M
2025	$4.4M	+8.8%	−$60M	-1365.7%	−$68M	-1537.4%	$40M
2024	$4.1M	-32.8%	−$53M	-1301.8%	−$54M	-1333%	$32M
2023	$6M	+142.6%	−$65M	-1074%			$40M
2022	$2.5M	+5737.6%	−$85M	-3411.1%
2021	$43K	0%	−$58M	-136879.4%
2020	$43K	—	−$14M	-33085.4%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Ocugen website traffic

Latest recorded traffic for Ocugen is 13K monthly website visits, down 23.5% over the last three months. Ocugen's team grew 26.5% over the past year.

Latest monthly visits13K 3-month web change-23.5% 1-year team growth+26.5%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Manager/ Sr Manager, Medical & Scientific WritingMalvern, Pennsylvania, 19355, United States, Northern America, Americas · Other · Aug 31, 2026 Clinical Trial ManagerMalvern, Pennsylvania, 19355, United States, Northern America, Americas · Other · Aug 10, 2026 Senior Clinical Trial ManagerMalvern, Pennsylvania, 19355, United States, Northern America, Americas · Other · Aug 10, 2026 TMF LeadMalvern, PA · CSM & Support · Aug 9, 2026 Senior Clinical Data ManagerMalvern, PA · Data Science & Engineering · Aug 6, 2026 Associate Director, Program ManagementMalvern, PA · Project Management · Aug 5, 2026 Business Development ManagerMalvern, PA · Business Development · Jul 16, 2026 VP of Finance OperationsMalvern, PA · Finance · Jul 11, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CTCell Care TherapeuticsDeveloping first-in-class stem cell derived biopharmaceuticals to treat inflammatory and degenerative ophthalmic diseases	Long Beach, United States	Operational	1	$5.3M	$17M
PTProQR TherapeuticsDevelops RNA therapies to potentially transform the lives of patients suffering from genetic rare diseases	Leiden, Netherlands	Operational
EPEyeGate PharmaceuticalsEyeGate Pharma \| Advanced therapeutics and drug delivery mechanisms for ophthalmic care	Waltham, United States	Operational
CBCan-Fite BioPharmaA biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities	Petah Tikva, Israel	Operational
STSling TherapeuticsA clinical-stage biopharmaceutical company developing an oral small molecule for the treatment of thyroid eye disease	Ann Arbor, United States	Operational
PUPulseMedicaBuilding revolutionary technology to image and treat vitreoretinal disease	Edmonton, Canada	Operational
OTOcuMension TherapeuticsCompany which focuses on the development of ophthalmic medications	Huangpu, China	Operational
QUQuetheraGene therapy company dedicated to improving the future treatment of common blinding eye diseases	Canterbury, United Kingdom	Acquired